Abbott to spend $2.9B on Latin American drugmaker

(AP)—Abbott Laboratories will spend about $2.9 billion to broaden its reach in Latin America with the acquisition of branded generic drugmaker CFR Pharmaceuticals.

Abbott makes like Similac as well as and drugs. The North Chicago, Illinois, company said Friday the will expand its presence in several fast-growing markets, especially with branded generic drugs.

An Abbott spokesman said generic drugs with are preferred in many developing markets due to their reputation for quality and consistent supply.

CFR Pharmaceuticals, which is based in Chile, sells more than 1,000 products in 15 Latin American markets. Abbott expects the deal to add about $900 million in revenue in 2015, the first full year after it is completed.

Abbott will buy the holding company that indirectly owns about 73 percent of CFR and then will conduct a cash tender offer for the remaining shares. The deal value tops $3 billion when counting about $430 million in debt.

Abbott will use cash to pay for the deal, which will have no impact on its 2014 earnings forecast. The drugmaker expects to close the acquisition by the end of the third quarter.

Shares of Abbott closed at $39.24 on Thursday, which puts them up about 2 percent so far this year. The stock had advanced 31 cents to $39.55 Friday about 45 minutes before markets opened.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Smith & Nephew to buy ArthroCare in $1.5B deal

Feb 03, 2014

British medical technology company Smith & Nephew plans to buy U.S. medical device maker ArthroCare in a $1.5 billion deal that it says will strengthen its sports medicine business.

Recommended for you

Added benefit of vedolizumab is not proven

6 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments